A Dipstick Test to Identify Post-ERCP Pancreatitis

A novel technology shows promise to help rule in (or rule out) this common problem.

Despite advances in technique and the routine use of rectal nonsteroidal anti-inflammatory drugs (NSAIDs), post–endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) develops in approximately 4%–7% of patients. Diagnosis is typically made via physical examination and laboratory testing. Now researchers report the performance of a dipstick-based test of urine trypsinogen-2 concentration to diagnose PEP.

Four hundred patients undergoing ERCP were prospectively enrolled. All received rectal NSAIDs. Plasma amylase testing and urine trypsinogen-2 and urine trypsinogen-2 with the dipstick tests were performed before ERCP, 4 hours post-ERCP, and 24 hours post-ERCP.

Among patients with a negative dipstick test at 0 hours, 58 had a …

Reviewing Author

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

A Dipstick Test to Identify Post-ERCP Pancreatitis

Topics

Reviewing Author